Eisai has announced that it has reached an agreement with Pfizer regarding the strategic alliance for the Alzheimer’s Disease treatment, Aricept (donepezil hydrochloride).
Reportedly Eisai and Pfizer have been in discussions to resolve their dispute concerning the strategic alliance and development agreement which was signed in October 1994.
Under the redefined alliance Eisai and Pfizer will continue to co-promote Aricept in the US, Japan and selective markets in Europe. The expiry of the agreement for the co-promotion of Aricept in Japan would cease as of 31st of December, 2012.
As per the new partnership, Eisai will co-promote pregabalin in Japan, a treatment for neuropathic pain developed by Pfizer.
Pfizer has launched pregabalin in the US and Europe with the brand name Lyrica and has filed a New Drug Application (NDA) in Japan.
Jeff Kindler, chairman and chief executive officer of Pfizer, said: “Our continued partnership with Eisai is a testament to Pfizer’s commitment to help patients suffering from Alzheimer’s disease. In addition, we look forward to forging a new alliance with Eisai to help treat neuropathic pain with our co-promotion of Lyrica in Japan following regulatory approval.”